期刊
MEDICAL ONCOLOGY
卷 29, 期 3, 页码 2046-2052出版社
HUMANA PRESS INC
DOI: 10.1007/s12032-011-9965-1
关键词
Fas; Fas ligand; Acute lymphoblastic leukemia; Childhood; Prognosis
类别
资金
- Shiraz University of Medical Sciences [4724]
The soluble forms of Fas and its ligand (sFas and sFasL) correlate with disease progression in various malignancies. We compared serum levels of sFas and sFasL in children with acute lymphoblastic leukemia and healthy children to determine the prognostic significance of these molecules. Serum levels of sFas and sFasL were measured with an enzyme-linked immunosorbent assay in 48 patients with newly diagnosed childhood acute lymphoblastic leukemia and 38 healthy children. Cut-off values of sFas and sFasL levels were based on their levels in controls. Clinical and laboratory characteristics were recorded on admission. The mean serum concentration of sFas was 243 +/- 40 pg/mL in patients and 238 +/- 29 pg/mL in controls. Serum levels of sFasL were 4.33 +/- 0.25 ng/mL in patients and 4.27 +/- 0.11 ng/mL in controls. Neither difference was significant. Based on the cut-off value, 12.5% of the patients were positive for sFas, and 16.6% were positive for sFasL. Survival was significantly longer in sFasL-positive patients (394 +/- 69.6 vs. 254 +/- 24.3 days) and the duration of complete remission was also longer (380 +/- 65.0 vs. 246 +/- 26.0 days) than in sFasL-negative patients (P < 0.02), indicating the important role of this molecule in the response to therapy. Higher sFas levels were associated with hepatosplenomegaly (P < 0.047). In conclusion, sFasL positivity was associated with a favorable outcome in ALL patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据